MedTrace Logo

Study of Silodosin to Facilitate Passage of Urinary Stones

NCT01144949 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 239

Last updated 2014-08-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.

Conditions

  • Ureteral Calculi
  • Kidney Stones
  • Urolithiasis

Interventions

DRUG

silodosin

one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks

DRUG

placebo

one placebo capsule orally, once daily, with food for up to 4 weeks

Sponsors & Collaborators

  • Watson Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Scott Olsen, MPH · Watson Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144949 on ClinicalTrials.gov